Literature DB >> 16399773

Effects of dietary daidzein and its metabolite, equol, at physiological concentrations on the growth of estrogen-dependent human breast cancer (MCF-7) tumors implanted in ovariectomized athymic mice.

Young H Ju1, Jodi Fultz, Kimberly F Allred, Daniel R Doerge, William G Helferich.   

Abstract

Genistein and daidzein are the main isoflavones in legumes. Equol is an intestinal bacterial metabolite of daidzein. In this study, we evaluated the estrogenic potential of daidzein and synthetic (+/-)-equol to stimulate growth of estrogen-dependent breast cancer (MCF-7) in vitro and in vivo. We hypothesize that estrogenic effects of daidzein and (+/-)-equol could modulate the growth of MCF-7 cells both in vitro and also once implanted into ovariectomized athymic mice. At concentrations between 0.001 and 50 microM, daidzein and (+/-)-equol stimulated the growth of MCF-7 cells with maximal stimulation at 1 muM in vitro. To evaluate their effects on the growth of MCF-7 cells implanted in ovariectomized athymic mice, two dietary dose-response studies [daidzein (125, 250, 500 and 1000 p.p.m.) and (+/-)-equol (250, 500 and 1000 p.p.m.)] were conducted. Tumor size and body weight were monitored weekly during the study. At completion of the study, we analyzed cellular proliferation of tumors using immunohistochemical staining (ki-67), pS2 expression in tumors using a real time quantitative reverse transcription-polymerase chain reaction (qRT-PCR), and total daidzein and (+/-)-equol levels in plasma using liquid chromatography-electrospray tandem mass spectrometry (LC-ES/MS/MS). Dietary daidzein had a slight but significant stimulatory effect on MCF-7 tumor growth in mice. No significant induction of pS2 mRNA (an estrogen-responsive marker) in tumors by dietary daidzein was observed. Total plasma daidzein concentrations in plasma were between 0.25 and 1.52 microM. Dietary equol treatment (for 37 weeks) did not stimulate MCF-7 tumor growth. There were no statistical differences in tumor size, proliferation and pS2 expression among any treatment groups. Total equol concentrations in plasma were 2.10-3.21 microM. In conclusion, daidzein and (+/-)-equol have proliferative effects on MCF-7 cell growth in vitro within the concentration range tested. Dietary daidzein had a slight but significant stimulatory effect on tumor growth, whereas (+/-)-equol did not stimulate the growth of estrogen-dependent breast tumor growth in athymic mice, increase the cell proliferation in tumors, or induce an estrogen-responsive pS2 expression. Total daidzein or (+/-)-equol plasma levels in mice fed the isoflavones were in the range that stimulated MCF-7 cell growth in vitro. These results suggest that pharmacokinetic and/or metabolic factors attenuate the estrogenic effects of daidzein and equol in vivo.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16399773     DOI: 10.1093/carcin/bgi320

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  38 in total

1.  Soy isoflavone phase II metabolism differs between rodents and humans: implications for the effect on breast cancer risk.

Authors:  Kenneth D R Setchell; Nadine M Brown; Xueheng Zhao; Stephanie L Lindley; James E Heubi; Eileen C King; Mark J Messina
Journal:  Am J Clin Nutr       Date:  2011-09-28       Impact factor: 7.045

Review 2.  Emerging research on equol and cancer.

Authors:  Johanna W Lampe
Journal:  J Nutr       Date:  2010-05-26       Impact factor: 4.798

3.  Isoflavones - Mechanism of Action and Impact on Breast Cancer Risk.

Authors:  Johannes Stubert; Bernd Gerber
Journal:  Breast Care (Basel)       Date:  2009-02-20       Impact factor: 2.860

4.  Estrogen effects on epithelial proliferation and benign proliferative lesions in the postmenopausal primate mammary gland.

Authors:  Charles E Wood; Joy M Hester; Susan E Appt; Kim R Geisinger; J Mark Cline
Journal:  Lab Invest       Date:  2008-07-07       Impact factor: 5.662

Review 5.  Effects of isoflavones on breast tissue and the thyroid hormone system in humans: a comprehensive safety evaluation.

Authors:  S Hüser; S Guth; H G Joost; S T Soukup; J Köhrle; L Kreienbrock; P Diel; D W Lachenmeier; G Eisenbrand; G Vollmer; U Nöthlings; D Marko; A Mally; T Grune; L Lehmann; P Steinberg; S E Kulling
Journal:  Arch Toxicol       Date:  2018-08-21       Impact factor: 5.153

6.  Dietary soy isoflavones increase metastasis to lungs in an experimental model of breast cancer with bone micro-tumors.

Authors:  Xujuan Yang; Aashvini Belosay; James A Hartman; Huaxin Song; Yukun Zhang; Wendan Wang; Daniel R Doerge; William G Helferich
Journal:  Clin Exp Metastasis       Date:  2015-03-08       Impact factor: 5.150

7.  Equol inhibits growth, induces atresia, and inhibits steroidogenesis of mouse antral follicles in vitro.

Authors:  Sharada Mahalingam; Liying Gao; Marni Gonnering; William Helferich; Jodi A Flaws
Journal:  Toxicol Appl Pharmacol       Date:  2016-02-11       Impact factor: 4.219

8.  The soy isoflavone equol may increase cancer malignancy via up-regulation of eukaryotic protein synthesis initiation factor eIF4G.

Authors:  Columba de la Parra; Elisa Otero-Franqui; Michelle Martinez-Montemayor; Suranganie Dharmawardhane
Journal:  J Biol Chem       Date:  2012-10-24       Impact factor: 5.157

9.  Estradiol increases ER-negative breast cancer metastasis in an experimental model.

Authors:  Xujuan Yang; Aashvini Belosay; Mengyuan Du; Timothy M Fan; Russell T Turner; Urszula T Iwaniec; William G Helferich
Journal:  Clin Exp Metastasis       Date:  2013-10-05       Impact factor: 5.150

10.  Effects of letrozole on breast cancer micro-metastatic tumor growth in bone and lung in mice inoculated with murine 4T1 cells.

Authors:  Wendan Wang; Aashvini Belosay; Xujuan Yang; James A Hartman; Huaxin Song; Urszula T Iwaniec; Russell T Turner; Mona I Churchwell; Daniel R Doerge; William G Helferich
Journal:  Clin Exp Metastasis       Date:  2016-05-21       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.